Evidence for accelerated desensitisation of 5-HT(2C) receptors following combined treatment with fluoxetine and the 5-HT(1A) receptor antagonist, WAY 100,635, in the rat

Neuropharmacology

Volumn 39, Issue 7, 2000, Pages 1222-1236

  Bristow, L J ^a   O'Connor, D ^a   Watts, R ^a   Duxon, M S ^a   Hutson, P H ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

5 HT(1A) receptor antagonist; 5 HT(2C) receptor; Chronic treatment; Serotonin re uptake inhibitor; Social interaction

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (1 METHYL 5 INDOLYL) 3 (3 PYRIDYL)UREA; 5 METHYLTHIO 1 (3 PYRIDYLCARBAMOYL) 6 (TRIFLUOROMETHYL)INDOLINE; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A ANTAGONIST; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; HABITUATION; LOCOMOTION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SOCIAL INTERACTION;

ANIMALS; BEHAVIOR, ANIMAL; FLUOXETINE; INDOLES; MALE; MOTOR ACTIVITY; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SOCIAL BEHAVIOR; UREA;

EID: 0034117399     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00191-4     Document Type: Article

References (38)

1. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives of General Psychiatry. 51:1994;248-251.
2. 1A antagonists. Trends in Neuroscience. 19:1996;378-383.
3. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology. 15:1995;217-222.
4. Bordet R., Thomas P., Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. American Journal of Psychiatry. 155:1998;1346-1351.
5. 2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines. Journal of Medical Chemistry. 41:1998;1598-1612.
6. 2B receptor protein in the rat central nervous system. Neuroscience. 76:1997;323-329.
7. 2B receptors in the medial amygdala causes anxiolysis in the social interaction test in the rat. Neuropharmacology. 36:1997;601-608.
8. Duxon M.S., Watts R., Bristow L.J. Differential effects of acute and chronic fluoxetine in the rat social interaction test. Journal of Psychopharmacology. 12(suppl. A):1998;A27.
9. 1A receptor function. Pharmacology, Biochemistry and Behavior. 62:1999;695-701.
10. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. British Journal of Pharmacology. 115:1995;1064-1070.
11. 2C receptors but not by sympathomimetic effects. Neuropharmacology. 33:1994;457-465.
12. Gundlah C., Hjorth S., Auerbach S.B. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: this effect persists after repeated citalopram treatment. Neuropharmacology. 36:1997;475-482.
13. 1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology. 36:1997;461-465.
14. Hollander E., DeCaria C., Gully R., Nitescu A., Suckow R.F., Gorman J.M., Klein D.F., Liebowitz M.R. Effects of chronic fluoxetine treatment on behavioural and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder. Psychiatry Research. 36:1991;1-17.
15. 1A receptor antagonists on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology. 36:1997;467-473.
16. Kennedy A.J., Gibson E.L., O'Connell M.T., Curzon G. Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP. Psychopharmacology. 113:1993;262-268.
17. 1C receptors and their therapeutic relevance. Current Opinion Invest. Drugs. 2:1993;317-362.
18. 2B receptor agonist, BW 723C86 on three rat models of anxiety. British Journal of Pharmacology. 117:1996;1443-1448.
19. 2C/2B receptor function. Neuropharmacology. 33:1994;1581-1588.
20. 1C receptor antagonists. European Journal of Pharmacology. 164:1989;445-454.
21. 2B receptor antagonist with anxiolytic-like properties. British Journal of Pharmacology. 117:1996;427-434.
22. 2C receptor antagonist. Neuropharmacology. 36:1997;609-620.
23. 2C/2B receptor antagonist. British Journal of Pharmacology. 111:1994;797-802.
24. Lightowler S., Kennett G.A., Williamson I.J.R., Blackburn T.P., Tullock I.F. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacology, Biochemistry and Behavior. 49:1994;281-285.
25. Maj J., Bijak M., Dziedzicka-Wasylewska M., Rogoz R., Skuza G., Tokarski T. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology. 127:1996;73-82.
26. Maj J., Moryl E. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. Journal of Neural Transmission [GenSect]. 88:1992;143-156.
27. Maj J., Moryl F. Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. European Neuropsychopharmacology. 3:1993;85-94.
28. Malagie I., Trillat A.C., Douvier E., Anmella M.C., Dessalles M.C., Jacquot C., Gardier A.M. Regional differences in the effect of the combined treatment of WAY 100,635 and fluoxetine: an in vivo microdialysis study. Naunyn-Schmiedebergs Archiv für Pharmakologie. 354:1996;785-790.
29. 2C receptor agonists: pharmacological characteristics and therapeutic potential. Journal of Pharmacology and Experimental Therapeutics. 286:1998;913-924.
30. 2C receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. European Neuropsychopharmacology. 6:1996;169-175.
31. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. The Lancet. 349:1997;1594-1597.
32. 1C/2 receptor agonists and antagonists. European Journal of Pharmacology (Molecular Pharmacology Section). 244:1993;1-5.
33. Romero L., Artigas F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors. Journal of Neurochemistry. 68:1997;2593-2603.
34. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology. 15:1996;349-360.
35. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology. 12:1997;81-89.
36. Whitton P., Curzon G. Anxiogenic-like effect of infusing 1-(3-chlorophenyl)piperazine (mCPP) into the hippocampus. Psychopharmacology. 100:1990;138-140.
37. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve antidepressant response? Journal of Clinical Psychopharmacology. 17:1997;446-450.
38. Zohar J., Insel T.R., Zohar-Kadouch R.C., Hill J.L., Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Archives of General Psychiatry. 45:1988;167-172.